These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 20682182)

  • 1. The revitalized tau hypothesis on Alzheimer's disease.
    Maccioni RB; Farías G; Morales I; Navarrete L
    Arch Med Res; 2010 Apr; 41(3):226-31. PubMed ID: 20682182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroimmunomodulation in the pathogenesis of Alzheimer's disease.
    Morales I; Farías G; Maccioni RB
    Neuroimmunomodulation; 2010; 17(3):202-4. PubMed ID: 20134203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease.
    Rojo LE; Fernández JA; Maccioni AA; Jimenez JM; Maccioni RB
    Arch Med Res; 2008 Jan; 39(1):1-16. PubMed ID: 18067990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid precursor protein cytoplasmic domain with phospho-Thr668 accumulates in Alzheimer's disease and its transgenic models: a role to mediate interaction of Abeta and tau.
    Shin RW; Ogino K; Shimabuku A; Taki T; Nakashima H; Ishihara T; Kitamoto T
    Acta Neuropathol; 2007 Jun; 113(6):627-36. PubMed ID: 17431643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau oligomers and aggregation in Alzheimer's disease.
    Meraz-Ríos MA; Lira-De León KI; Campos-Peña V; De Anda-Hernández MA; Mena-López R
    J Neurochem; 2010 Mar; 112(6):1353-67. PubMed ID: 19943854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoaspartate formation and neurodegeneration in Alzheimer's disease.
    Shimizu T; Watanabe A; Ogawara M; Mori H; Shirasawa T
    Arch Biochem Biophys; 2000 Sep; 381(2):225-34. PubMed ID: 11032409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease.
    Huang HC; Jiang ZF
    J Alzheimers Dis; 2009; 16(1):15-27. PubMed ID: 19158417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau.
    Hardy J; Duff K; Hardy KG; Perez-Tur J; Hutton M
    Nat Neurosci; 1998 Sep; 1(5):355-8. PubMed ID: 10196523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
    Padmanabhan J; Levy M; Dickson DW; Potter H
    Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Significance of tau in the development of Alzheimer's disease].
    Takashima A
    Brain Nerve; 2010 Jul; 62(7):701-8. PubMed ID: 20675874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment strategy of Alzheimer's disease: pause in clinical trials of Abeta vaccine and next steps].
    Kuzuhara S
    Brain Nerve; 2010 Jul; 62(7):659-66. PubMed ID: 20675870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. beta-Secretase, APP and Abeta in Alzheimer's disease.
    Vassar R
    Subcell Biochem; 2005; 38():79-103. PubMed ID: 15709474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease: Abeta, tau and synaptic dysfunction.
    LaFerla FM; Oddo S
    Trends Mol Med; 2005 Apr; 11(4):170-6. PubMed ID: 15823755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Involvement of beta-amyloid in the etiology of Alzheimer's disease].
    Tomiyama T
    Brain Nerve; 2010 Jul; 62(7):691-9. PubMed ID: 20675873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes.
    David DC; Ittner LM; Gehrig P; Nergenau D; Shepherd C; Halliday G; Götz J
    Proteomics; 2006 Dec; 6(24):6566-77. PubMed ID: 17111439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease.
    Boche D; Donald J; Love S; Harris S; Neal JW; Holmes C; Nicoll JA
    Acta Neuropathol; 2010 Jul; 120(1):13-20. PubMed ID: 20532897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transgenic mouse models of Alzheimer's disease: phenotype and application.
    Higgins GA; Jacobsen H
    Behav Pharmacol; 2003 Sep; 14(5-6):419-38. PubMed ID: 14501255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights from Drosophila models of Alzheimer's disease.
    Cowan CM; Shepherd D; Mudher A
    Biochem Soc Trans; 2010 Aug; 38(4):988-92. PubMed ID: 20658990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease?
    Götz J; Ittner LM; Kins S
    J Neurochem; 2006 Aug; 98(4):993-1006. PubMed ID: 16787410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteases and lipoprotein receptors in Alzheimer's disease.
    Makarova A; Williams SE; Strickland DK
    Cell Biochem Biophys; 2004; 41(1):139-78. PubMed ID: 15371644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.